KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Inventory (2016 - 2025)

Historic Inventory for Astrazeneca (AZN) over the last 17 years, with Q4 2025 value amounting to $6.6 billion.

  • Astrazeneca's Inventory rose 2399.77% to $6.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $6.6 billion, marking a year-over-year increase of 2399.77%. This contributed to the annual value of $6.6 billion for FY2025, which is 2399.77% up from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's Inventory is $6.6 billion, which was up 2399.77% from $6.6 billion recorded in Q3 2025.
  • Astrazeneca's Inventory's 5-year high stood at $10.5 billion during Q3 2021, with a 5-year trough of $4.3 billion in Q1 2021.
  • For the 5-year period, Astrazeneca's Inventory averaged around $6.0 billion, with its median value being $5.5 billion (2023).
  • As far as peak fluctuations go, Astrazeneca's Inventory soared by 19102.96% in 2021, and later crashed by 5176.67% in 2022.
  • Over the past 5 years, Astrazeneca's Inventory (Quarter) stood at $9.0 billion in 2021, then tumbled by 47.69% to $4.7 billion in 2022, then rose by 15.43% to $5.4 billion in 2023, then dropped by 2.51% to $5.3 billion in 2024, then grew by 24.0% to $6.6 billion in 2025.
  • Its last three reported values are $6.6 billion in Q4 2025, $6.6 billion for Q3 2025, and $6.5 billion during Q2 2025.